In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate

The emergence and rapid spread of the Omicron variant of SARS-CoV-2, which has more than 30 substitutions in the spike glycoprotein, compromises the efficacy of currently available vaccines and therapeutic antibodies. Using a clinical strain of the Omicron variant, we analyzed the neutralizing power...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; pp. 4683 - 5
Main Authors Touret, Franck, Baronti, Cécile, Bouzidi, Hawa Sophia, de Lamballerie, Xavier
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 18.03.2022
Nature Publishing Group
Nature Portfolio
Subjects
631/326/596/1296
631/326/596/4130
Antibodies
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Antibodies, Viral - therapeutic use
COVID-19 Drug Treatment
Humanities and Social Sciences
Humans
Membrane Glycoproteins
Monoclonal antibodies
multidisciplinary
Neutralization Tests
SARS-CoV-2
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Spike glycoprotein
Spike Glycoprotein, Coronavirus
Viral Envelope Proteins
Online AccessGet full text

Cover

More Information
Summary:The emergence and rapid spread of the Omicron variant of SARS-CoV-2, which has more than 30 substitutions in the spike glycoprotein, compromises the efficacy of currently available vaccines and therapeutic antibodies. Using a clinical strain of the Omicron variant, we analyzed the neutralizing power of eight currently used monoclonal antibodies compared to the ancestral B.1 BavPat1 D614G strain. We observed that six of these antibodies have lost their ability to neutralize the Omicron variant. Of the antibodies still having neutralizing activity, Sotrovimab/Vir-7831 shows the smallest reduction in activity, with a factor change of 3.1. Cilgavimab/AZD1061 alone shows a reduction in efficacy of 15.8, resulting in a significant loss of activity for the Evusheld cocktail (42.6-fold reduction) in which the other antibody, Tixagevimab, does not retain significant activity against Omicron. Our results suggest that the clinical efficacy of the initially proposed doses should be rapidly evaluated and the possible need to modify doses or propose combination therapies should be considered.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-08559-5